Moreover, certain eating patterns, like smaller, more frequent meals, can ease digestive processes
GLP1 players seem barely have the bandwidth to think about other therapeutic areas right now
Conclusions The present review elucidates the physiological benefits of synthetic incretin-based medications, highlighting both their unprecedented clinical efficacy against T2D and obesity and their extensive non-target metabolic benefits against heart, kidney, and liver diseases
These treatments enhance those helpful signals, making them tools for diabetes and weight management
New research underway More trials are now starting to look at how GLP-1s might influence things like chronic inflammation or immunosuppression, both of which might contribute to cancer growth
Most patients begin noticing appetite and craving changes within the first 12 weeks